Effect of mycophenolate mofetil and enteric-coated mycophenolate sodium on blood concentration in renal transplant recipients
-
摘要:
目的 探讨吗替麦考酚酯(MMF)与麦考酚钠肠溶片(EC-MPS)在同等生物效应剂量下对肾移植受体麦考酚酸(MPA)血药浓度和不良反应的影响。 方法 回顾性分析106例活体供肾移植受体的临床资料。按肾移植术后服用不同药物分为两组,MMF组(M1组,62例)和EC-MPS组(M2组,44例)。两组受体的免疫抑制方案分别为M1组用他克莫司(FK506)+MMF+泼尼松,M2组用FK506+EC-MPS+泼尼松。分析两组受体服药后1、2、3周和1、2、3个月MPA血药浓度的变化情况、不良反应发生情况及服用药物所花费用。 结果 采取同等生物效应给药,服药后第1、2、3周,第1、2、3个月时M1组MPA血药谷浓度比M2组低,各个时间点两组间比较,差异均有统计学意义(均为P < 0.05)。与M1组比较,M2组术后不良反应的发生率较低且症状较轻。采用同等生物学效应给药,M1组服用MMF所花费用1 710元/月,M2组服用EC-MPS所花费用2 736元/月,但M1组因治疗药物不良反应所产生费用远高于M2组。 结论 同等的生物效应剂量下服用EC-MPS的患者相对服用MMF的患者能维持更高的MPA血药浓度并且不良反应更少。 Abstract:Objective To evaluate the effect of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) on the blood concentration of mycophenolic acid (MPA) and adverse events in renal transplant recipients at the equivalent biologically effective dose. Methods Clinical data of 106 recipients undergoing living-donor kidney transplantation were retrospectively analyzed. According to the drugs taken after renal transplantation, all recipients were divided into the MMF (M1 group, n=62) and EC-MPS groups (M2 group, n=44). In the M1 group, tacrolimus (FK506) + MMF + prednisone was delivered and FK506 + EC-MPS + prednisone was given in the M2 group. The changes of blood concentration of MPA were analyzed at 1-, 2-, 3-week, 1-, 2- and 3-month after drug administration. The incidence of adverse events and the drug cost were also analyzed. Results The drugs were administered at the same biologically effective dose. At each time point after drug administration, the trough blood concentration of MPA in the M1 group was significantly lower than that in the M2 group (all P < 0.05). Compared with the M1 group, the incidence and severity of adverse events were significantly less in the M2 group. The cost of taking MMF in the M1 group was 1 710 Yuan/month, whereas 2 736 Yuan/month for taking EC-MPS in the M2 group. However, the cost of treating drug-induced adverse events in the M1 group was significantly higher than that in the M2 group. Conclusions Patients taking EC-MPS at the same biologically effective dose can maintain higher blood concentration of MPA and suffer from fewer adverse events than their counterparts receiving MMF. -
表 1 两组受体服药后不良反应发生情况
Table 1. The incidence of adverse events of recipients between the two groups after administration [n(%)]
组别 n 重症肺部感染 中重度胃肠道症状 急性排斥反应 移植物失功 其他 M1组 62 5(8) 9(15) 4(6) 1(2) 1(2) M2组 44 1(2) 2(5) 1(2) 0 1(2) -
[1] THURET R, KLEINCLAUSS F, TERRIER N, et al. Challenges in renal transplantation[J]. Prog Urol, 2016, 26(15): 1001-1044. DOI: 10.1016/j.purol.2016.09.056. [2] BUDDE K, GLANDER P, KRÄMER BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes[J]. Transplantation, 2007, 83(4): 417-424. doi: 10.1097/01.tp.0000251969.72691.ea [3] 李朋梅, 张相林, 唐崑, 等.人血浆中霉酚酸浓度测定方法研究及药物监测应用[J].中国药学杂志, 2007, 42(19): 1490-1493. DOI: 10.3321/j.issn:1001-2494.2007.19.015.LI PM, ZHANG XL, TANG K, et al. Determination of mycophenolic acid concentration in human plasma and its application to therapeutic drug monitoring in renal transplantation patient[J]. Chin Pharmaceut J, 2007, 42(19): 1490-1493. DOI: 10.3321/j.issn:1001-2494.2007.19.015. [4] 李沭, 陈文倩, 张相林.肾移植患者术后免疫抑制治疗中的吗替麦考酚酯药物暴露分析[J].中国药学杂志, 2017, 52(7): 602-608. DOI: 10.11669/cpj.2017.07.017.LI S, CHEN WQ, ZHANG XL. Analysis of mycophenolate mofetil exposure in kidney transplant patients receiving immunosuppressive therapy[J]. Chin Pharmaceut J, 2017, 52(7): 602-608. DOI: 10.11669/cpj.2017.07.017. [5] MATHEW BS, FLEMING DH, ANNAPANDIAN VM, et al. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period[J]. Ther Drug Monit, 2010, 32(2): 136-140. DOI: 10.1097/FTD.0b013e3181cd550f. [6] JIA Y, PENG B, LI L, et al. Estimation of mycophenolic acid area under the curve with limited-sampling strategy in Chinese renal transplant recipients receiving enteric-coated mycophenolate sodium[J]. Ther Drug Monit, 2017, 39(1): 29-36. DOI: 10.1097/FTD.0000000000000360. [7] 吕海金, 易慧敏.实体器官移植受者的免疫功能测定研究进展[J].器官移植, 2014, 5(4): 257-260. DOI: 10.3969/j.issn.1674-7445.2014.04.014.LYU HJ, YI HM. Advance on detection of immune function of recipients after solid organ transplantation[J]. Organ Transplant, 2014, 5(4): 257-260. DOI: 10.3969/j.issn.1674-7445.2014.04.014. [8] CALABRESE DR, FLOREZ R, DEWEY K, et al. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients[J]. Clin Transplant, 2018: e13332. DOI: 10.1111/ctr.13332. [9] WANG P, MAO Y, RAZO J, et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients[J]. Pharmacogenomics, 2010, 11(10): 1389-1402. DOI: 10.2217/pgs.10.105. [10] FILLER G, ALVAREZ-ELÍAS AC, MCINTYRE C, et al. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy[J]. Pediatr Nephrol, 2017, 32(1): 21-29. doi: 10.1007/s00467-016-3352-2 [11] PARK S, KIM YS, LEE J, et al. Reduced tacrolimus trough level is reflected by estimated glomerular filtration rate (eGFR) changes in stable renal transplantation recipients: results of the OPTIMUM phase 3 randomized controlled study[J]. Ann Transplant, 2018, 23: 401-411. DOI: 10.12659/AOT.909036. [12] MARTINEZ-MIER G, SALAZAR-RAMIREZ A. The cost of gastrointestinal adverse events and the impact of dose-reductions/discontinuations on acute rejection in kidney transplant patients of mycophenolate mofetil-related compared to enteric-coated mycophenolate sodium: a pharmacoeconomic study[J]. Transplant Proc, 2016, 48(2): 588-595. DOI: 10.1016/j.transproceed.2016.02.017. [13] FENG JJ, ZHANG LW, ZHAO P, et al. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil[J]. Int J Clin Pract Suppl, 2015(183): 1-7. DOI: 10.1111/ijcp.12660. [14] YAO X, HUANG H, WEI C, et al. Limited sampling strategy for mycophenolic acid in Chinese kidney transplant recipients receiving enteric-coated mycophenolate sodium and tacrolimus during the early posttransplantation phase[J]. Ther Drug Monit, 2015, 37(4): 516-523. DOI: 10.1097/FTD.0000000000000170. [15] 姚志勇, 孙斌, 洪泉, 等.肾移植术后分别应用麦考酚钠和吗替麦考酚酯两种免疫抑制方案的比较[J].武警后勤学院学报(医学版), 2015, 24(6): 434-437. http://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201506005.htmYAO ZY, SUN B, HONG Q, et al. Comparison between the two immunosuppressive regimens after renal transplantation: enteric-coated mycophenolate sodium versus mycophenolate mofetil[J]. J Log Univ PAP (Med Sci), 2015, 24(6): 434-437. http://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201506005.htm [16] HWANG HS, HYOUNG BJ, KIM S, et al. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus[J]. J Korean Med Sci, 2010, 25(12): 1759-1765. DOI: 10.3346/jkms.2010.25.12.1759. [17] LANGONE A, SHIHAB F, PANKEWYCZ O, et al. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation[J]. Clin Transplant, 2014, 28(9): 961-967. DOI: 10.1111/ctr.12392. [18] 王振, 钱叶勇, 李昆, 等.活体供肾移植急性排斥反应发生与供受者年龄的关系[J].解放军医学院学报, 2015, (10): 1025-1028. DOI: 10.3969/j.issn.2095-5227.2015.10.017.WANG Z, QIAN YY, LI K, et al. Relationship between acute rejection in living donor kidney transplantation and age of donors and recipients[J]. Acad J Chin PLA Med Sch, 2015, (10): 1025-1028. DOI: 10.3969/j.issn.2095-5227.2015.10.017.